Notably, a panel of cancer specialists at the Advanced Prostate Cancer Consensus Conference 2019 rated PSMA PET as the preferred imaging modality for detecting clinical progression (80–87% consensus), and for confirming a CT/scintigraphy-based diagnosis of oligorecurrent oligometastatic PCa (75% consensus) in patients with BCR [66]. Here, FOLH1 is linked to cancer.